Evaluation of galectin-3 and intestinal fatty acid binding protein as serum biomarkers in autosomal recessive polycystic kidney disease

被引:3
作者
Fleischer, Lindsay T. [1 ]
Ballester, Lance [2 ]
Dutt, Mohini [3 ]
Howarth, Kathryn [3 ]
Poznick, Laura [4 ]
Darge, Kassa [4 ,5 ]
Furth, Susan L. [3 ,6 ]
Hartung, Erum A. [3 ,6 ]
机构
[1] Rowan Univ, Cooper Med Sch, Camden, NJ USA
[2] Childrens Hosp Philadelphia, Biostat & Data Management Core, Philadelphia, PA 19104 USA
[3] Childrens Hosp Philadelphia, Div Nephrol, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA
[4] Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA
[5] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA
[6] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
Autosomal recessive polycystic kidney disease; Congenital hepatic fibrosis; Biomarkers; Chronic kidney disease; Portal hypertension; Ultrasound elastography; CONGENITAL HEPATIC-FIBROSIS; PROGRESSION; CHILDREN; EXPRESSION; CHILDHOOD; DIAGNOSIS; ENCODES; PATIENT; VOLUME; MODEL;
D O I
10.1007/s40620-022-01416-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Autosomal recessive polycystic kidney disease (ARPKD) causes fibrocystic kidney disease, congenital hepatic fibrosis, and portal hypertension. Serum galectin-3 (Gal-3) and intestinal fatty acid binding protein (I-FABP) are potential biomarkers of kidney fibrosis and portal hypertension, respectively. We examined whether serum Gal-3 associates with kidney disease severity and serum I-FABP associates with liver disease severity in ARPKD. Methods Cross-sectional study of 29 participants with ARPKD (0.2-21 years old) and presence of native kidneys (Gal-3 analyses, n= 18) and/or native livers (I-FABP analyses, n= 21). Serum Gal-3 and I-FABP were analyzed using enzyme linked immunosorbent assay. Kidney disease severity variables included estimated glomerular filtration rate (eGFR) and height-adjusted total kidney volume (htTKV). Liver disease severity was characterized using ultrasound elastography to measure liver fibrosis, and spleen length and platelet count as markers of portal hypertension. Simple and multivariable linear regression examined associations between Gal-3 and kidney disease severity (adjusted for liver disease severity) and between I-FABP and liver disease severity (adjusted for eGFR). Results Serum Gal-3 was negatively associated with eGFR; 1 standard deviation (SD) lower eGFR was associated with 0.795 SD higher Gal-3 level (95% CI - 1.116, - 0.473; p < 0.001). This association remained significant when adjusted for liver disease severity. Serum Gal-3 was not associated with htTKV in adjusted analyses. Overall I-FABP levels were elevated, but there were no linear associations between I-FABP and liver disease severity in unadjusted or adjusted models. Conclusions Serum Gal-3 is associated with eGFR in ARPKD, suggesting its value as a possible novel biomarker of kidney disease severity. We found no associations between serum I-FABP and ARPKD liver disease severity despite overall elevated I-FABP levels. [GRAPHICS] .
引用
收藏
页码:133 / 145
页数:13
相关论文
共 60 条
  • [1] Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD)
    Adeva, M
    El-Youssef, M
    Rossetti, SO
    Kamath, PS
    Kubly, V
    Consugar, MB
    Milliner, DM
    King, BF
    Torres, VE
    Harris, PC
    [J]. MEDICINE, 2006, 85 (01) : 1 - 21
  • [2] [Anonymous], HUMAN FABP2 I FABP Q
  • [3] [Anonymous], PEDIAT CHRONIC KIDNE
  • [4] BAO Q, 1995, J CELL SCI, V108, P2791
  • [5] Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD)
    Bergmann, C
    Senderek, J
    Windelen, E
    Küpper, F
    Middeldorf, I
    Schneider, F
    Dornia, C
    Rudnik-Schöneborn, S
    Konrad, M
    Schmitt, CP
    Seeman, T
    Neuhaus, TJ
    Vester, U
    Kirfel, J
    Büttner, R
    Zerres, K
    [J]. KIDNEY INTERNATIONAL, 2005, 67 (03) : 829 - 848
  • [6] ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies
    Bergmann, Carsten
    [J]. PEDIATRIC NEPHROLOGY, 2015, 30 (01) : 15 - 30
  • [7] Bullock SL, 2001, J AM SOC NEPHROL, V12, P515, DOI 10.1681/ASN.V123515
  • [8] Early childhood height-adjusted total kidney volume as a risk marker of kidney survival in ARPKD
    Burgmaier, Kathrin
    Kilian, Samuel
    Arbeiter, Klaus
    Atmis, Bahriye
    Buescher, Anja
    Derichs, Ute
    Dursun, Ismail
    Duzova, Ali
    Eid, Loai Akram
    Galiano, Matthias
    Gessner, Michaela
    Gokce, Ibrahim
    Haeffner, Karsten
    Hooman, Nakysa
    Jankauskiene, Augustina
    Koerber, Friederike
    Longo, Germana
    Massella, Laura
    Mekahli, Djalila
    Milosevski-Lomic, Gordana
    Nalcacioglu, Hulya
    Rus, Rina
    Shroff, Rukshana
    Stabouli, Stella
    Weber, Lutz T.
    Wygoda, Simone
    Yilmaz, Alev
    Zachwieja, Katarzyna
    Zagozdzon, Ilona
    Doetsch, Joerg
    Schaefer, Franz
    Liebau, Max Christoph
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [9] Giardiasis Alters Intestinal Fatty Acid Binding Protein (I-FABP) and Plasma Cytokines Levels in Children in Brazil
    Cascais-Figueiredo, Tiara
    Austriaco-Teixeira, Phelipe
    Fantinatti, Maria
    Silva-Freitas, Maria Luciana
    Santos-Oliveira, Joanna Reis
    Coelho, Camila H.
    Singer, Steven M.
    Da-Cruz, Alda Maria
    [J]. PATHOGENS, 2020, 9 (01):
  • [10] The Role of Galectin-3 in the Kidneys
    Chen, Szu-Chia
    Kuo, Po-Lin
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (04)